Lidocaine May Kill Infants When Used For Teething Pain: FDA

Federal drug regulators are warning that the oral painkiller lidocaine should not be given to teething infants, due to a risk that it may cause severe injury or death.  

The FDA issued a drug safety communication and consumer update  on June 26, warning that prescription oral viscous lidocaine 2% should not be used for infants or children experiencing teething pain.

The agency has ordered that a boxed warning be placed on the prescription information label, which is the strongest label warning the FDA can require.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

According to reports submitted to the FDA’s Adverse Event Reporting System (FAERS), there have been at least 22 reported cases of oral viscous lidocaine 2% toxicity affecting children and infants under the age of 3.5 years. Of those cases, at least six resulted in the death of the child, three were life-threatening, 11 of the children ended up hospitalized, and two required medical intervention but not hospitalization.

Health experts often estimate that only about 10% of all adverse drug events are actually reported to FAERS, meaning the number of children actually injured or killed by oral use of lidocaine could be significantly higher.

The drug safety communication also reiterates the agency’s 2012 warning against the use of over-the-counter benzocaine gels and liquids, sold under the brand names like Anbesol, Hurricaine and Orajel.

The FDA warns that even after issuing the earlier warning, it continues to receive reports of children suffering a condition known as methemoglobinemia due to OTC benzocaine use. Methemoglobinemia dangerously decreases the amount of oxygen carried in the blood, and can cause injury or even death.

Additionally, in 2010, Standard Homeopathic Company had to issue a Hyland’s Teething Tablet recall following an FDA warning that it was also linked to child injury risks. The recalled tablets contained varying amounts of belladonna, a potentially toxic ingredient, and the FDA had received a number of FAERS reports suggesting children had suffered belladonna toxicity after ingesting the pills.

The FDA also got reports that children had taken more pills than they should because the manufacturer had not supplied a child-proof cap.

In this week’s warning, the FDA recommended parents simply avoid the use of all topical pain relievers for the treatment of teething pain.

“Topical pain relievers and medications that are rubbed on the gums are not necessary or even useful because they wash out of the baby’s mouth within minutes,” according to the FDA warning. “When too much viscous lidocaine is given to infants and young children or they accidentally swallow too much, it can result in seizures, severe brain injury, and problems with the heart. Cases of overdose due to wrong dosing or accidental ingestion have resulted in infants and children being hospitalized or dying.”

The agency urges parents to follow the recommendations of the American Academy of Pediatrics, which recommends that parents to use a chilled, but not frozen, teething ring to soothe teething pain, or to simply gently rub the child’s gums with your fingers to soothe the pain.

1 Comments

  • JavierFebruary 3, 2016 at 5:41 am

    Where it happen?

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Master Complaint Outlines Allegations in Ozempic, Wegovy, Mounjaro Lawsuits in MDL
Master Complaint Outlines Allegations in Ozempic, Wegovy, Mounjaro Lawsuits in MDL (Posted today)

Plaintiffs pursuing GLP-1 injury lawsuits have filed a Master Complaint outlining common allegations being pursued against Novo Nordisk and Eli Lilly over their diabetes and weight loss drugs, including Ozempic, Wegovy, Mounjaro and others.

Six Years of Depo-Provera Injections Caused Woman To Develop Intracranial Meningioma: Lawsuit
Six Years of Depo-Provera Injections Caused Woman To Develop Intracranial Meningioma: Lawsuit (Posted yesterday)

California woman indicates she was unaware there was a link between her meningioma and Depo-Provera injections until a study was published in March 2024, resulting in widespread publicity about the brain tumor risks.